1. Sverdlov, E.D., Genetic surgery—a right strategy to attack cancer, Curr. Gene Ther., 2011, vol. 11, no. 6, pp. 501–531.
2. Matthews, T. and Boehme, R., Antiviral activity and mechanism of action of ganciclovir, Rev. Infect. Dis., 1988, vol. 10, no. 3, Suppl., pp. S490–S494.
3. Kurozumi, K., Tamiya, T., Ono, Y., et al., Apoptosis induction with 5–fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus, J. Neuro–Oncol., 2004, vol. 66, nos. 1–2, pp. 117–127.
4. Mesnil, M. and Yamasaki, H., Bystander effect in herpes simplex virus–thymidine kinase/ganciclovir cancer gene therapy: Role of gap–junctional intercellular communication, Cancer. Res., 2000, vol. 60, no. 15, pp. 3989–3999.
5. Collins, S.A., Buhles, A., Scallan, M.F., et al., AAV2–mediated in vivo immune gene therapy of solid tumours, Genet. Vaccines Ther., 2010, vol. 8, p. 8. doi 10.1186/1479–0556–8–8